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Background: The study aim was to determine the effect of a dietary intervention on growth, body composition and resting energy expenditure
(REE) in children with cystic ﬁbrosis (CF) and pancreatic insufﬁciency (PI) in a randomized, double blind, placebo-controlled trial.
Methods: Subjects (5 to 17 yrs) participated in a 12-month trial of the organized lipid matrix LYM-X-SORB™ (LXS) vs. placebo dietary
supplements with similar calories, total fat and fatty acids. Dietary intake was assessed using 3-day weighed food records. Height (HAZ), weight
(WAZ), BMI (BMIZ), mid-upper arm muscle (UAMAZ) and fat area (UAFAZ) Z-scores were calculated. Fat mass (FM) and fat-free mass (FFM)
were obtained by whole body DXA. REE (kcal/d) was evaluated by indirect calorimetry at baseline, 3 and 12 months and %REE calculated using
Schoﬁeld equations. No growth or REE differences were observed between LXS and placebo groups so data were pooled for analysis.
Results: 63 children (57% males, age 10.6 ± 2.9 yr, 43% receiving LXS) completed REE measurements. Caloric intake increased from a median
of 2502 [1478, 4909] to 2616 [1660, 4125] kcal/d at 12 months. HAZ, WAZ and UAMAZ increased (p b 0.05) over 12 months. Mean REE was
109 ± 8% predicted at baseline and 107 ± 9% at 12 months (p b 0.05). REE (kcal/d) adjusted for FFM and FM decreased over 12 months
([mean ± SE] −31 ± 12 kcals, p b 0.01), signiﬁcant only in males (−49 ± 16 kcals, p b 0.01).
Conclusions: Over a 12 month nutrition intervention with either LXS or placebo, the growth status, muscle stores and REE improved. Sustained
increased energy intake improved energy metabolism, growth and nutritional status in school age children with CF, PI and mild lung disease.
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Cystic fibrosis (CF) is one of the most common chronic,
multi-system inheritable diseases. Most children with CF, in
addition to pulmonary disease, suffer from pancreatic insuffi-
ciency (PI) and the nutritional consequences of lifelong
malabsorption [1]. Chronic fat malabsorption may result in
malnutrition, growth failure, and fat-soluble vitamin, essential
fatty acid and choline deficiencies [2–4]. The treatment of fat
malabsorption remains a challenge for the CF care team.
Considering recent CF Foundation and Registry data from theby Elsevier B.V. All rights reserved.
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high rate [1]. Malnutrition and poor growth in clinically stable
children with CF and PI result from chronic negative energy
balance due to insufficient caloric intake to overcome modestly
higher energy requirements, related to the variable degree of
energy loss from malabsorption and the mildly increased
resting energy expenditure (REE) [5–13].
These data were collected as part of a randomized, placebo
controlled trial of LYM-X-SORB™ (LXS, Avanti Polar Lipids,
Alabaster, AL) to evaluate choline status in children with CF and
PI. LXS is a choline-rich structured lipid matrix that has
previously been shown to be absorbable without pancreatic
enzyme therapy and to improve nutritional status and clinical
outcomes for children with CF and PI [14]. The second
generation LXS used in the present protocol had improved
palatability and solubility characteristics, and was designed to be
mixed with a variety of foods and beverages. The aim of this
report was to evaluate the changes in dietary intake, growth, body
composition and REE occurring over 12 months of daily
supplementation with either LXS or the isocaloric placebo.
2. Methods
Study participants ages 5.0 to 17.9 years with CF and PI from
ten CF Centers were evaluated from March 2007 to May 2011.
This study was approved by the Institutional Review Board of the
Children's Hospital of Philadelphia (CHOP) and at each CF
Center. Verbal assent was obtained from the subjects b18 yrs of
age with written consent from their parents/guardians. Exclusion
criteria were FEV1 b40% predicted, residual pancreatic lipase
activity (fecal elastase N15 μg/g stool), liver disease as defined as
a serum GGT N3× reference range or other chronic health
conditions that may affect gastrointestinal absorption or growth.
After enrollment, subjects were randomized to receive daily
supplementation with either LXS or placebo powder. The
random allocation sequence was generated by the CHOP
Research Pharmacy who assigned participants to their groups
with stratification for age and sex. LXS was composed of
lysophosphatidylcholine, triglycerides and essential fatty acids.
The placebo had similar calories, total fat and fatty acids with
similar macronutrient distribution (kcal protein 6%, carbohy-
drate 58% and lipid 34%). LXS contained more choline than
placebo (295 vs 39 mg/packet). Both powder supplements
were mixed with wheat flour and sugar, provided in sealed
packets (32 g/packet) with identical appearance, and mixed
with a variety of food and beverage. All subjects and study
team were blinded to group assignment. Subjects between the
ages of 5.0 and 11.9 years consumed two packets per day
(64 g/d of powder with 304 kcal/d), and ages 12.0 to
18.9 years consumed three packets per day (96 g/d with
456 kcal/d). LXS and placebo were produced by Avanti Polar
Lipids, Inc. (Alabaster, AL) and the calorie, macronutrient and
micronutrient content was verified in an independent laboratory
(Eurofins Inc., Des Moines, IA) using standard methods.
Subjects completed study visits at CHOP following an
overnight admission in the Clinical and Translational Research
Center (CTRC) at baseline and after 3 and 12 months ofsupplementation. Dietary intake was assessed at each time point
using 3-day weighed food records. Subjects and parents/guardians
were provided with measuring cups, spoons, a digital food scale
and detailed verbal and written instructions to weigh and record
each food/beverage consumed. Completed diet records were
reviewed and analyzed by the CTRC research nutritionist using
Nutrition Data System for Research software (National Coordinat-
ing Center, University of Minnesota, Minneapolis, MN). Energy
intake was assessed using the Dietary Reference Intakes [15], and
expressed as percent Estimated Energy Requirement (%EER) for
active children. The “active” physical activity level for the
calculation of %EER has been found to best approximate the total
energy requirements in children with CF and PI [16]. Families
were contacted by telephone every 28 days to report adherence
based on number of packets consumed over the previous
28 days. These data were used to calculate an average percent
adherence as a measure of overall adherence for the two intervals
(cumulative adherence estimates: baseline until 3 months and
baseline until 12 months. However, when adjusting LXS and
placebo nutrient intake at the 3 and 12 month dietary assess-
ments, we used an adherence estimate close (within one month)
to the dietary assessment (proximate adherence estimate).
Growth, body composition and REE were assessed at
baseline, 3 and 12 months. Weight was measured to the nearest
0.1 kg using an electronic scale (Scaletronix, White Plains, NY)
and height to the nearest 0.1 cm using a stadiometer (Holtain,
Crymych, UK). Age- and sex-specific standard deviation scores
(Z-scores) for weight (WAZ), height (HAZ) and bodymass index
(BMIZ) were calculated [17]. Mid-upper arm circumference was
measured using a linen tapemeasure (McCoy,MarylandHeights,
MO). A skinfold caliper (Holtain, Crymych, UK) was used to
measure tricep skinfold thickness on the right side. Upper arm
muscle and fat areas were derived, and z scores for upper arm
muscle area (UAMAZ) and upper arm fat area (UAFAZ) were
computed [18]. Total fat-free mass (FFM), fat mass (FM) and
percent body fat were obtained by whole body dual energy X-ray
absorptiometry (DXA, Delphi A, Hologic, Inc., Bedford, MA).
Pubertal status was determined using Tanner stages with a
validated self-assessment questionnaire [19].
REE was measured by open circuit indirect calorimetry using a
computerized metabolic cart (SensorMedics Spectra, Yorba
Linda, CA). In preparation for the REE, each subject received a
standardized eveningmeal followed by a 12-hour fast. The subject
was awakened on the day of study and restricted to minimal
physical activity. A 60-minute REE assessment was performed
between 7 and 10 AM. Data from the first 10 min and from
periods of documented physical movement or coughing were
omitted and the remaining data averaged. REE was calculated
from the modified Weir equation [20]. REE was compared to
predicted values derived from the Schofield equations that adjust
for age, sex, weight and height [21]. Pulmonary function was
evaluated by standard methods for spirometry [22] using a
MedGraphics spirometer (Medical Graphics Corporation, Minne-
apolis, MN). FEV1% predicted was calculated using Wang et al.
[23] and Hankinson et al. [24] equations. Adverse events from
patient report every 28 days, and frommedical record reviewwere
collected.
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for each outcome. Descriptive statistics were calculated for
continuous variables using means and standard deviations for
normally distributed data and medians and ranges for skewed
data, and for categorical variables using frequency distribu-
tions. Cross-sectional comparisons of growth and nutritional
status, body composition, pulmonary function and REE
between supplementation groups (LXS vs. placebo) and
between sexes were performed using Student's independent
samples t test for normally distributed and Mann–Whitney U
test for skewed data. Comparisons of categorical variables
between groups were assessed with chi-squared or Fisher's
exact test. Changes in dietary intake, growth, body composition
and REE were explored by supplementation groups at 3 and
12 months. As there was no group difference, data were pooled
and this report focuses on the results of this global nutrition
intervention (LXS and placebo combined). Trends over time
for the whole sample were assessed using Student's dependent
samples t-test or Wilcoxon matched pairs signed ranks test as
appropriate.
Longitudinal analyses of REE were performed to assess
significant change from baseline over the two time points (3
and 12 months) using the longitudinal mixed effects (LME)
analysis procedure in STATA (XTREG) [25]. LME models
were run separately by supplementation group (LXS and
placebo group) and then for the total sample. Both FFM and
FM were entered into all models as predictors of REE as they
are known to be the main predictors of REE in children and
adults [26]. Other potential predictors such as sex, age, FEV1,Table 1
Characteristics (mean ± SD) at baseline for LYM-X-SORB™ (LXS) and Placebo g
All
n = 63
LXS
n = 27
Sex, % males 57 61
Age, y 10.6 ± 2.9 11.0 ± 2.8
Pubertal Tanner stage, %
1 47 42
2 29 31
3 13 15
4 10 12
5 2 0
Genotype, ΔF508/508, % 57 56
HAZ −0.5 ± 0.9 −0.2 ± 0.9
WAZ −0.4 ± 0.7 −0.5 ± 0.6
BMIZ −0.2 ± 0.7 −0.5 ± 0.6
Body composition
FFM, kg 26.3 ± 9.4 26.8 ± 8.1
FM, kg 7.1 ± 2.6 7.3 ± 2.8
Fat, % 21.6 ± 5.7 21.5 ± 5.1
UAMAZ −0.6 ± 0.8 −0.8 ± 0.8
UAFAZ −0.3 ± 0.8 −0.4 ± 0.8
FEV1, % pred 96 ± 22 92 ± 21
REE, kcal/d 1300 ± 256 1314 ± 222
REE % 108.5 ± 8.3 108.8 ± 8.6
BMIZ— body mass index-Z-score; FFM— fat-free mass (kg); FM— fat mass (kg)
arm fat area Z-score; UAMAZ — upper arm muscle area Z-score; WAZ — weight
⁎ Differences signiﬁcant at p b 0.05.
⁎⁎ Differences signiﬁcant at p b 0.01.
⁎⁎⁎ Differences signiﬁcant at p b 0.001.pubertal status, total energy intake (dietary plus LXS or
placebo) and average adherence to 3 and 12 months were
explored. The models were also tested separately by sex and by
supplementation group. All statistical analyses were performed
using STATA 12.0 (College Station, TX). Results were
considered significant at P b 0.05, and data are presented as
means ±SD (normal distribution) or median [range] (skewed
distribution).
3. Results
Of the 70 children who completed 12 months, 7 were
excluded from the analysis because REE measurements were
not available (test failure). Of the 63 children with complete
growth, body composition and REE measurements (57%
males, age 10.6 (2.9) yrs), 11 were excluded from the dietary
analysis because of missed record or no record, or poor quality
of the dietary record. At baseline, these children with CF had
suboptimal growth and nutritional status, mild lung disease and
mildly elevated REE (Table 1). LXS and placebo groups were
similar with the exception of BMIZ (higher in placebo). Males
and females were similar and only differed in total body FFM
(higher in males), percent fat (higher in females) and REE as
kcal/d (higher in males). The seven children with incomplete
data and omitted from analyses were not different at baseline
from the 63 with complete data in age, sex, growth, maturity
status, body composition, or REE.
Details for the calories and macronutrient intake are
presented in Table 2 for 52 children with complete longitudinalroups, and for male and female participants.
Placebo
n = 36
Male
n = 36
Female
n = 27
52 100 0
10.2 ± 2.9 11.0 ± 2.5 10.1 ± 3.2
50 46 48
28 31 26
11 14 11
8 6 15
3 3 0
58 58 56
−0.7 ± 0.9 −0.4 ± 0.7 −0.6 ± 1.1
−0.3 ± 0.7 −0.4 ± 0.7 −0.5 ± 0.7
0.1 ± 0.7 ⁎⁎⁎ −0.2 ± 0.6 −0.2 ± 0.8
26.0 ± 10.4 28.5 ± 9.8 23.5 ± 8.2 ⁎
6.9 ± 2.5 6.6 ± 2.6 7.7 ± 2.5
21.7 ± 6.2 18.9 ± 5.0 25.1 ± 4.6 ⁎⁎⁎
−0.4 ± 0.8 −0.6 ± 0.9 −0.5 ± 0.7
−0.2 ± 0.9 −0.3 ± 0.7 −0.3 ± 1.0
100 ± 22 92 ± 28 88 ± 27
1290 ± 282 1385 ± 264 1187 ± 198 ⁎⁎
108.3 ± 8.1 109.0 ± 8.4 107.9 ± 8.2
; HAZ— height-Z-score; REE— resting energy expenditure; UAFAZ— upper
-Z-score.
Table 2
Total calories and macronutrient intake (median [range]) in LYM-X-SORB™ (LXS) and Placebo groups at baseline, 3 and 12 months.
All
n = 52 a
LXS
n = 20
Placebo
n = 32
Baseline 3 mo 12 mo Baseline 3 mo 12 mo Baseline 3 mo 12 mo
Total intake, kcal/d 2502
[1478, 4909]
2581
[1609, 3620]
2616
[1660, 4125]
2561
[1841, 3504]
2678
[1731, 3620]
2611
[1660, 4005]
2437
[1478, 4909]
2440
[1609, 3571]
2623
[1704, 4125]
EER, % 123
[64, 223]
125
[77, 221]
122
[69, 213]
120
[86, 153]
125
[77, 173]
125
[69, 165]
127
[64, 223]
124
[77, 221]
120
[81, 213]
Fat, g/d 97
[54, 227]
97
[51, 180]
102
[59, 203]
109
[61,145]
99
[66, 173]
93
[59, 183]
94
[54, 227]
96
[51, 180]
103
[69, 203]
Fat, %kcal 36
[23, 53]
34
[19, 49]
36
[27, 47]
36
[27, 42]
31
[24, 49]
35
[27, 46]
37
[23, 53]
35
[19, 46]
36
[28, 47]
Protein, g/d 82
[46, 170]
83
[38, 137]
86
[36, 167]
82
[54, 119]
85
[59, 133]
85
[36, 135]
80
[46, 170]
77
[38, 137]
86
[45, 167]
Protein, %kcal 13
[9, 24]
13
[8, 19]
13
[9, 23]
13
[9, 20]
13
[9, 17]
13
[9, 17]
13
[9, 24]
12
[8, 19]
13
[9, 23]
Carbohydrates, g/d 318
[179, 604]
349
[192, 583]
315
[203, 559]
325
[239, 474]
391
[192, 522]
325
[238, 516]
305
[179, 604]
347
[231, 583]
308
[203, 559]
Carbohydrates, %kcal 51
[34, 69]
53
[33, 70]
52
[38, 63]
52
[43, 63]
53
[33, 66]
52
[38, 61]
51
[34, 69]
53
[41, 70]
51
[39, 63]
EER — estimated energy requirement.
a Of the 63 subjects, 52 had complete dietary data; LXS and placebo supplement intake was adjusted for proximate adherence (diet intake not adjusted).
Table 3
Growth, body composition and REE in all subjects (n = 63) at baseline, 3 and
12 months.
Mean ± SD Baseline 3 mo 12 mo
HAZ −0.5 ± 0.9 −0.4 ± 0.9 ⁎⁎⁎ −0.4 ± 0.9 ⁎⁎⁎
WAZ −0.4 ± 0.7 −0.3 ± 0.7 ⁎⁎⁎ −0.3 ± 0.8 ⁎
BMIZ −0.2 ± 0.7 −0.0 ± 0.7 ⁎⁎ −0.2 ± 0.9
Body composition
FFM, kg 26.3 ± 9.4 27.5 ± 9.7 ⁎⁎⁎ 29.6 ± 10.9 ⁎⁎⁎
FM, kg 7.1 ± 2.6 7.6 ± 2.8 ⁎⁎⁎ 8.0 ± 3.0 ⁎⁎⁎
Fat, % 21.6 ± 5.7 22.1 ± 5.6 ⁎ 21.8 ± 5.8
UAMAZ −0.6 ± 0.8 −0.4 ± 0.8 ⁎ −0.3 ± 1.0 ⁎⁎
UAFAZ −0.3 ± 0.8 −0.1 ± 0.8 ⁎⁎ −0.2 ± 0.9
REE, kcal/d 1300 ± 256 1335 ± 260 ⁎⁎ 1353 ± 276 ⁎⁎⁎
REE % 108.5 ± 8.3 108.9 ± 7.8 106.5 ± 8.5 ⁎
BMIZ— body mass index-Z-score; FFM— fat-free mass (kg); FM— fat mass
(kg); HAZ — height-Z-score; LXS — LYM-X-SORB™; REE — resting
energy expenditure; UAFAZ— upper arm fat area Z-score; UAMAZ— upper
arm muscle area Z-score; WAZ — weight-Z-score.
⁎ Change over time signiﬁcant at p b 0.05.
⁎⁎ Change over time signiﬁcant at p b 0.01.
⁎⁎⁎ Change over time signiﬁcant at p b 0.001.
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omitted from analyses were not different from these children in
age, sex, baseline growth and maturity status, body composi-
tion, REE, or dietary intake. The median total caloric intake
was 2502 [1478, 4909] kcal/d at baseline and increased to 2616
[1660, 4125] kcal/d at 12 months. Following the introduction
of the supplements, dietary adaptation resulted in a decrease in
the caloric intake from food. The proportion of the total calories
contributed by LXS or placebo supplement at 12 months was
adjusted for percent adherence at the time of the dietary recall.
Adherence proximate to their 3-day dietary intake was 78%,
with no difference between those on LXS (75%) and placebo
(80%).
The changes in growth status, body composition and REE over
3 and 12 months are presented in Table 3. No difference was
observed between LXS and placebo group over time, and the data
were pooled. HAZ,WAZ and UAMAZ improved (p b 0.05) over
12 months, with no change in UAFAZ. Both FFM and FM
increased (p b 0.001) during the study. Changes over time in
growth and nutritional status were not different betweenmales and
females. REE decreased (p b 0.05) from 108.5 ± 8.3% to
106.5 ± 8.5% predicted over 12 months. From the LME model
(Table 4), FFM, FM, sex and time were significant predictors of
REE (kcal/d), explaining 87% of the variance (p b 0.001). REE
adjusted for FFM and FM decreased by 31 ± 12 kcal/d between
baseline and 12 months in all subjects, and females had lower
REE as kcal/d overall. LME analysis was then performed
separately by sex. In males, adjusted REE decreased by 49 ±
16 kcal/d over 12 months (R2 = 0.88, p b 0.01, n = 36), while
there was no change over time in females. This decrease in REE
over time for males was found in both LXS and placebo
supplementation groups (results not shown). Age, puberty status,
average % adherence, FEV1 and total energy intake were tested in
the models but were not significant predictors of REE (not
shown). Adherence calculated for the whole time period frombaseline to either 3 months or 12 months (cumulative adherence
estimate) was 78% with no difference between supplementation
groups. Adverse events were typical of the expected course of CF
participants over 12 months and no adverse events were attributed
to the study.
4. Discussion
Over a 12 month dietary intervention, the total caloric intake
increased by a median of 114 kcal/d, after adjusting intake for
adherence (adjustment for supplement intake only). Confound-
ing factors such as the impact of the dietary assessment itself on
nutritional intake or clinically driven changes in treatment may
influence caloric intake. Over the course of the study, there
Table 4
Longitudinal mixed effect model (LME): REE (kcal/d) over time in all subjects
and by sex.
Coef. SE p-Value N Overall R2 Overall p-value
All 63 0.87 b0.001
FFM, kg 0.02 0.001 b0.001
FM, kg 0.01 0.004 0.02
Sex, female −79 23 0.001
Time 3 mo −0.2 11 0.98
Time 12 mo −31 12 0.01
Constant 775 48 b0.001
Male 36 0.88 b0.001
FFM, kg 0.02 0.001 b0.001
FM, kg 0.009 0.005 0.1
Time 3 mo −11 15 0.5
Time 12 mo −49 16 0.002
Constant 697 43 b0.001
Female 27 0.80 b0.001
FFM, kg 0.02 0.003 b0.001
FM, kg 0.01 0.007 0.2
Time 3 mo 14 18 0.4
Time 12 mo −8 19 0.7
Constant 618 52 b0.001
FFM — fat-free mass (kg); FM — fat mass (kg); LME — longitudinal mixed
effect model.
REE — resting energy expenditure (kcal/d); SE — standard error.
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intake or activity. Growth status and muscle stores were
suboptimal at baseline and improved over 12 months in all
subjects. The REE was mildly elevated at baseline as expected
[5–13] and decreased during a period of enhanced caloric
intake and documented increase in body size and muscle stores.
Nutritional status in CF is correlated with clinical outcomes and
survival [27], and normal nutrition status is among the goals of
clinical care. In the present study, an improvement in WAZ and
HAZ of 0.1 z-score over one year was achieved. This increase
corresponds to a clinically meaningful improvement from the 31st
to the 35th percentile for children beginning at −0.5 z-score. The
increase in muscle status (UAMAZ) from −0.6 to −0.3 z-score
represents an even greater improvement from the 28th to the 38th
percentile over one year. This 12-month average improvement in
Z-scores is likely meaningful because, as a group, these children
with CFmaintained their typical rate of accretion of FFM and FM,
and then had increased rates of accretion (‘catch-up growth’).
Few have studied the impact of an oral caloric intervention
in children with CF. In the Stark et al. study, the improvement
over nine weeks in caloric intake and weight was shown to
be greater with a combination of behavioral and nutrition
education interventions versus the nutrition education alone
[28]. In follow-up with this cohort, the growth of both the
behavioral and nutrition education intervention group and
nutrition education group, was similar from 3 to 24 months. In
later analysis, the combined behavioral and nutrition interven-
tion or nutrition education alone were both shown to result in a
smaller decline in BMIZ over about 2 years, when compared to
an age-matched sample of children from the CF Foundationpatient registry [29]. Smyth and Walters recently completed a
Cochrane review of three randomized or quasi-randomized
trials where oral calorie supplements were compared to dietary
counseling in people with CF who were either PI or pancreatic
sufficient [30]. An increased caloric intake with oral supple-
ments was documented at 12 months, but no differences were
observed in HAZ, WAZ, BMIZ, body composition or lung
function in these children with CF and suboptimal nutritional
status prior to intervention. In contrast, the present nutrition
intervention study of a caloric supplement added to participant
selected foods and beverages, resulted in a sustained increased
caloric intake over 12 months and achieved an improvement in
growth status, muscle stores, and REE.
Children with CF and PI have been shown to have a 5 to 20%
increased REE compared to predicted values for healthy subjects
[5–13]. In the present study, REE decreased over one year.
Interestingly, males showed a decrease in REE over time while
females did not. Sex differences in CF are well established, with
poorer growth and health outcomes for females [31–33]. In three
longitudinal studies following children with CF over one, two or
three years, REE either increased or remained elevated over time
as the participants aged [6,13,34]. Contrary to these observational
studies, a decrease in REE was observed with our nutrition
intervention over one year. Furthermore, our intervention may
have prevented further increase in REE and/or worsening in
energy balance often observed as children and adolescents with
CF grow older [6,13,34]. This reduction in REE likely supported
the observed growth and body composition status improvement.
FFM (mainly skeletal, muscle and organs) is the most powerful
predictor of REE, and FM is small but often statistically
significant in healthy children and adults and also in people
with chronic diseases [8,26]. The energy expenditure interactions
are complex across the age, sex, pubertal status and disease
severity spectrum. It remains unclear if an association between
REE and pulmonary function exists in children with mild to
moderate CF [6–13]. In the present study of clinically stable
school-age subjects with mild pulmonary disease, FEV1 was not
a significant predictor of REE.5. Conclusion
Over a 12 month nutrition intervention with either LXS or
placebo, the growth status, muscle stores and REE improved.
Sustained increased energy intake improved energy metabo-
lism, growth and nutritional status in school age children with
CF, PI and mild lung disease. Further studies of nutritional
intervention using powdered caloric supplements to commonly
consumed foods and beverages to treat growth faltering in
children or weight loss in adults with CF should be considered.Acknowledgments
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